ADDF Statement on Topline Results of Phase 3 Trial of Amyloid-Clearing Drug Lecanemab

While not a magic bullet, the modest effectiveness of lecanemab reported by Eisai/Biogen would give physicians one part of the treatment puzzle—combination therapies remain the holy grail NEW YORK, Sept. 28, 2022 /PRNewswire/ — The Alzheimer’s Drug Discovery Foundation (ADDF) is…

Click here to view original post